<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB/A
(Mark One)
/X/ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the fiscal year ended 12/31/99
/ / TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
(No Fee Required)
For the transition period from _________ to ___________
Commission file number 0-27123
MEDIQUIK SERVICES, INC.
---------------------------------------------
(Name of small business issuer in its charter)
DELAWARE 74-2876711
- ------------------------------- ---------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
4295 SAN FELIPE, SUITE 200, HOUSTON, TEXAS. 77027
- ------------------------------------------- ---------------------------------
(Address of principal executive offices) (Zip Code)
Issuer's telephone number (713) 888-1919
--------------
Securities registered under Section 12(b) of the Exchange Act:
TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED
------------------- -----------------------------------------
- ---------------------------------- -----------------------------------------
- ---------------------------------- -----------------------------------------
Securities registered under Section 12(g) of the Exchange Act:
COMMON STOCK, $.001 PAR VALUE PER SHARE
- --------------------------------------------------------------------------------
(Title of class)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Yes /X/ No / /
================================================================================
<PAGE>
Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. /X/
State issuer's revenues for its most recent fiscal year. $982,292
State the aggregate market value of the voting stock held by non-affiliates
computed by reference to the price at which the stock was sold, or the average
bid and asked prices of such stock, as of a specified date within the past 60
days.
As of 04/29/2000: $6,863,988.24
State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date:
6,032,007 shares of the Company's Common Stock issued and outstanding
at December 31, 1999.
Transitional Small Business Disclosure Format (Check one): Yes / /; No /X/
<PAGE>
PART I.
ITEM 1. DESCRIPTION OF THE BUSINESS
BUSINESS DEVELOPMENT
MediQuik Services, Inc. (the "Company" or "MediQuik") was organized
to take advantage of an identified niche market related to the delivery of
health care, medical and pharmaceutical supplies. This market is the management
of chronic disease patients for managed care payors by providing home delivery
of pharmaceuticals and supplies, educational materials, and patient monitoring
and consultations. These payors include self-insured, self-administered
employers of all sizes, small to moderate sized health insurance companies and
small to moderate sized health maintenance organizations, preferred provider
organizations, and third-party administrators. The Company's first product is a
Diabetes management program that includes Diabetes pharmaceutical and medical
supplies. As this product matures, the Company intends to offer other chronic
disease management products, such as respiratory management and congestive heart
failure management services. Historically, as a cost saving and time saving
strategy, MediQuik has contracted with other entities to receive, bundle and
deliver goods and services rather than develop the necessary resources in-house.
The Company's predecessor, also chartered under the name "MediQuik
Services, Inc.," was organized in Delaware on April 7, 1998 ("Old MediQuik").
Effective December 31, 1998, Old MediQuik was merged with and into Cash Flow
Marketing, Inc., a Delaware corporation ("Cash Flow"). Cash Flow was the
surviving corporation and changed its name to MediQuik Services, Inc. Cash Flow
was originally organized in Colorado on July 9, 1997, and changed its domicile
to Delaware effective December 31, 1998. At the time of the merger, Cash Flow
was a "shell" corporation with substantially no assets, business or operations.
Pursuant to the terms of the merger, each stockholder of Old
MediQuik received one share of common stock of the Company, $.001 par value per
share ("Common Stock"), for each .9327 shares of common stock of Old MediQuik
held by such stockholder. Each stockholder of Cash Flow received one share of
Company Common Stock for each two shares of Cash Flow common stock held by such
stockholders.
BUSINESS OF THE ISSUER
In recent years, the demand for higher quality health care with
reduced cost has prompted dramatic changes in the United States health care
system. Managed care organizations have emerged to control costs. Today, more
than two-thirds of all Americans with private health insurance are enrolled in
these plans.
MediQuik was organized to take advantage of these changes in the
delivery of health care. The Company provides chronic disease management
services to patients pursuant to contracts with managed care payors. MediQuik's
services include home delivery of pharmaceuticals, supplies and educational
materials, as well as patient monitoring and
<PAGE>
consultation services. MediQuik's customers include self-insured,
self-administered employers of all sizes, small to moderate sized health
maintenance organizations, third-party administrators and preferred provider
organizations. By entering into agreements with the managed care payors,
rather than individual patients, the Company believes that it will be able to
rapidly obtain a larger patient base. When MediQuik enters into a contract
with a managed care payor it typically becomes an approved provider for
thousands of patients who may select MediQuik's products and services,
ordinarily at a nominal cost to the patient. (Co-pay charges typically
represent less than 20% of the price of MediQuik's products and services).
Other providers generally sell directly to patients. For them, one sale
ordinarily results in one patient.
Generally, the Company enters into agreements with managed care
payors which provide that, in consideration of being designated as a plan
provider, the Company will provide services to plan participants at a discounted
rate. The Company also offers capitated service contracts pursuant to which the
managed care payor reimburses the Company based on the total number of
participants in the plan rather than based on the amount of products and
services actually consumed by the participants. Under capitated service
contracts, MediQuik would share a portion of the risk related to program costs
with the managed care payor. MediQuik is currently offering capitated services
contracts to managed care payors but has not entered into any such contracts to
date.
The Company's first product is a Diabetes management program, the
major profit component of which is the delivery of self testing supplies
(test strips, lancets and alcohol prep pads) directly to the home of the
patient. Diabetes Mellitus is the most common and most costly chronic disease
in the United States. In a release dated November 1, 1998, the National
Center for Chronic Disease Prevention and Health Promotion of the Centers for
Disease Control and Prevention (the "CDC") estimated that 15.7 million people
in the United States, or 5.9% of the population, have Diabetes. Of that
number only about 10.3 million have been diagnosed. According to the American
Diabetes Association, in 1997 the per capita costs of health care for people
with Diabetes was $10,071 per year. Further, the Company believes that it
will be positioned to provide services to an aging population with greater
incidences of Diabetes.
There is no cure for Diabetes. The disease can be controlled, but
only if the patient is willing to actively participate in that control. In
order to control Diabetes, the patient must regularly determine personal
blood sugar levels. This is normally done at home by the patient and is a
simple and relatively painless process. Patients use a lancet to prick a
finger and draw a drop of blood that is deposited upon a test strip. The test
strip is then introduced into a glucometer that displays the patient's blood
sugar level a few seconds later.
The Company believes that it can provide pharmaceuticals for the
treatment of Diabetes to patients covered by managed care providers and to
other MediQuik customers at substantial cost savings when compared with
alternative delivery systems. MediQuik has focused on preventive Diabetes
care products and services and has successfully negotiated supply contracts
that permit the Company to purchase large quantities of Diabetes care
products at favorable prices. In addition, by providing educational materials
and patient
<PAGE>
monitoring and consultation services, the Company believes that it will
provide better patient management, which reduces a patient's need for
hospitalization and prevents the development of other chronic diabetic health
related problems. After a patient is enrolled in the program, the Company
will ship supplies to the patient's home bimonthly or quarterly. Because of
the chronic nature of the disease, the Company expects its medical and
financial relationship with a patient to continue for many years. As of
December 31, 1999, the Company had entered into the following major provider
agreements:
Major Providers:
National HealthCare Alliance, Inc. Integranet
MultiPlan, Inc. BCBS of Texas
USA Managed Care Organization, Inc. Advantage Care Network
Cooperative Health Services of Colorado Benefit Services, Inc.
SMC Benefits Services ProMed Health
Diocese of Lafayette Mediversal
Americaid
The provider agreements generally provide that, in consideration
of being designated as a plan provider, the Company will provide products and
services to plan participants at a discounted rate. The provider agreements
typically have a term of one to two years with provisions for automatic
renewal unless terminated at the election of either party.
The Company's agreements with its current purchasers described
above will continue from year to year unless terminated by either party. The
Company anticipates, however, that the revenue to be generated by its major
provider agreements in the future will exceed the revenue generated from its
current purchasers.
To support its business activity, MediQuik has formed a strategic
alliance with Bayer Corporation, a worldwide leader in the manufacturing and
supply of Diabetes related products ("Bayer"). The Company has entered into a
Mail Order and Mail Order Health Plan Patient Testing Compliance Agreement
(the "Mail Order Agreement"). Pursuant to the Mail Order Agreement, the Company
has committed to purchase a certain volume of products from Bayer at a set
price. In consideration of the Company's agreement to provide certain customer
information to Bayer, Bayer has agreed to credit the Company's account based
on the amount of the Company's purchase commitment. If the Company does not
meet its purchase commitment, Bayer will charge the Company the difference
between the credit given for its purchase commitment and the credit given for
the amount actually purchased. As a result of the Bayer agreements, Bayer
products are available to the Company at deeply discounted prices. The Bayer
agreements allow MediQuik to sell Bayer products to managed care payors and
long-term care facilities. The Company purchases approximately 90% of its
products from Bayer. The Mail Order Agreement will expire 120 days after
either party gives the other notice of its termination.
<PAGE>
After MediQuik achieves meaningful market penetration with the
Diabetes management product, the Company intends to develop and offer
respiratory management and congestive heart failure management services.
In May 1999, MediQuik formed an 80% owned subsidiary known as
ChronicRx.com to provide Internet-based pharmacy services. ChronicRx.com will
focus on the chronic care niche and will specialize in prescription and
non-prescription medicines and management products used to treat chronic
diseases of all kinds. ChronicRx.com will provide 24-hour access to
pharmacists, educational material regarding the diagnosis, symptoms and
treatment of chronic illnesses, prescription and over-the-counter drugs, and
personal care products for chronic disease patients. The Company believes
that a number of factors poise ChronicRx.com for rapid growth: its access to
discounted pharmaceuticals through its relationship with MediQuik; the
availability of cost efficient mail-order distribution and the low cost and
the wide market reach of the Internet. The Company believes that ChronicRx.com
will be one of the first pharmacies on the Internet focused primarily on the
management of chronic diseases. The Company anticipates that ChronicRx.com
will begin offering on-line pharmacy services by the end of June 2000.
ChronicRx.com also offers access to the Daily Health Zone, an
interactive personal health management web site which provides information
concerning preventative healthcare, nutrition, fitness and wellness.
ChronicRx.com provides access to the web site to MediQuik's employer and
managed care provider customers whose employees or plan participants,
respectively, are permitted to access the web site for daily self-improvement
tips, questions and answers, self-tests, news, reviews, and searchable health
data. The web site permits employers and managed care providers to reward use
of the web site by providing incentives based on frequency of activity. The
Daily Health Zone web site is hosted by Murray Hill Communications, Inc. The
Company is negotiating with Murray Hill in connection with the execution of a
final agreement to purchase a license for the web site.
The Company anticipates that ChronicRx.com will become a wholly
owned subsidiary of the Company. The Company has reached agreements with the
minority members to redeem their interests in the subsidiary. The Company has
reached agreements with investors who have contributed cash to ChronicRx.com
to exchange their interests in ChronicRx.com for shares in the Company at
$1.75 per share.
As a cost saving and time saving strategy, management has
historically elected to outsource major components of the business.
Historically, the Company has outsourced order fulfillment, billing,
collections, utilization reporting, legal and accounting services and a
portion of sales force. However, by December 31, 1999, the Company developed
and implemented in-house enrollment, customer service, billing and
collections departments. The Company intends to hire a chief financial
officer with experience in working for public companies during the year 2000.
COMPETITION
The business of providing blood sugar monitoring supplies by mail
order is an
<PAGE>
immature industry characterized by high growth rates, low barriers to enter
the business, and many small competitors. Of the many companies that are mail
order providers of blood glucose monitoring supplies, most do not directly
compete with MediQuik because they generally concentrate on Medicare patients
by direct solicitation, rather than focusing on health care payors. To the
knowledge of the Company, each sells to patients rather than payors under
distribution agreements with the major manufacturers that provide for
relatively small price discounts. The Company believes that these companies
have little or no impact on the business of MediQuik. For them, one sale
results in one patient. For MediQuik, one sale will likely produce hundreds
or thousands of patients.
Several companies do compete with MediQuik in the traditional fee
for service market. MediQuik is aware of two companies that have exclusive
marketing agreements with certain manufacturers that target payors as clients
rather than individual patients. National Diabetic Pharmacies, Inc. ("NDP"),
is based in Roanoke, Virginia. NDP works primarily with diabetic managed care
patients and has approximately $18,000,000 in annual sales. NDP distributes
products manufactured by Boehringer Mannheim. TM Supply, Inc. doing business
as Total Medical Supply, located in Dothan, Alabama also competes with the
Company. It has a distribution agreement with Home Diagnostics, Inc., which
manufactures health care products. The Company believes that Total Medical
Supply has historically concentrated on Medicare business but has begun to
shift into the managed care private sector. MediQuik believes that neither
NDP nor Total Medical Supply is currently soliciting capitated agreements.
MediQuik has developed a program that shares cost containment
directly with the payor, which makes MediQuik effective as both a capitated
fee and a fee for service provider. MediQuik believes that it is the first
company in its industry to offer capitated fee contracts. Under such an
arrangement, a managed care payor would make payments to the Company based on
the total number of participants in its plan rather than the amount of
products and services actually consumed by its participants. Under capitated
fee contracts the Company risks that the cost of products and services it
provides will exceed fees paid, but the Company believes that capitated
contracts will create a financial commonality of interest with its potential
clients. Once payor clients recognize the advantages of capitated agreements,
the Company believes that its competitors will adopt this strategy. The
Company believes that it should acquire market share as quickly as possible.
MediQuik is currently offering capitated service contracts to managed care
payors but has not entered into any such contracts to date.
THE INDUSTRY
The U.S. demand for Diabetes monitoring and maintenance,
supplies, pharmaceuticals and equipment is expected to grow from $4.692
billion in 2000 to $6.545 billion by 2005. According to a March 1996 report
of the Genesis Group Associates, Inc. entitled "The Diabetes Dilemma Managing
Markets and Technology" (the "Genesis Report"), both the U.S. population and
the incidence of Diabetes in the U.S. population appear to be increasing. The
Genesis Report also indicates that on a worldwide basis, Johnson & Johnson,
Boehringer Mannheim, Bayer and MediSense, Inc. are the major manufacturers in
the field.
<PAGE>
Effective July 1, 1998, Medicare coverage was extended pursuant to the
Balanced Budget Act of 1997 to permit the reimbursement of Diabetes
self-testing supplies, as well as educational and training services for
Diabetes. Management of the Company believes that managed care payors will
view Medicare's reimbursement guidelines as the baseline for pricing these
products and services.
MARKET SEGMENTATION. The Company believes that there are five
business models in the market for Diabetes testing supplies, pharmaceuticals
and equipment:
1. RETAIL PHARMACIES. Retail pharmacies typically offer a range
of products from different manufacturers that are available without
prescription. Purchasers may be reimbursed directly by their insurance
carrier or Medicare for Diabetes care products. Most payors, including
Medicare, reimburse patients for the cost of the supplies less annual
deductible and co-payment amounts. Rules for qualification and reimbursement
for private insurance and Medicaid patients vary from state to state.
2. MANAGED CARE PROVIDERS. Some managed care providers distribute
Diabetes care products directly to patients covered by their plan. The
Company understands that many managed care providers have distribution
agreements with certain manufacturers of Diabetes care products.
3. MAIL ORDER. Mail order suppliers often enroll patients
directly and do not depend on managed care payor referrals. Mail order
suppliers tend to concentrate on Medicare patients and often have
distribution agreements with each of the major manufacturers. Mail order
suppliers usually handle billing and collecting from third-party payors for
the patient. The patient is responsible to the supplier for deductible and
co-pay amounts.
4. MANAGED CARE REFERRED PROVIDERS. Certain providers receive
patient referrals directly from managed care providers. Of the three
companies the Company knows in this segment, the Company believes that each
has an exclusive agreement with a manufacturer that provides a pricing
advantage over other supply sources. The Company offers significant price
discounts to the payors and attempts to secure agreements whereby the managed
care provider waives deductible and co-payment amounts for their patients.
5. CAPITATED FEE PROVIDERS. Although the Company is not aware of
any provider of Diabetes services that offer a capitated fee arrangement, the
Company has, itself developed such a system. Under capitated fee
arrangements, the Company agrees to provide certain Diabetes-related services
for a group of patients for a fixed fee. MediQuik believes that it is the
only company prepared to enter into agreements with payors to share in the
financial risk of patient treatment.
CHARACTERISTICS OF DIABETES. Diabetes is a disease characterized
by high levels of blood glucose. During the normal digestion process, the
body converts food into glucose (sugar) to be used by the body's cells as a
source of energy. Insulin, a hormone produced by the pancreas gland, is
necessary for normal utilization of glucose by most cells in the body. In
<PAGE>
people with Diabetes, insulin is either absent, not produced in sufficient
amounts, or the body does not respond to the insulin that is produced.
Without insulin or effective use of insulin, the body cannot use glucose for
energy. Instead, glucose builds up in the blood, creating high sugar levels
in the body. Diabetes is typically categorized into four types:
1. Type 1 Diabetes was previously called Insulin-Dependent
Diabetes Mellitus or Juvenile-Onset Diabetes. According to the CDC, Type 1
Diabetes may account for 5% to 10% of all diagnosed cases of Diabetes. Risk
factors contributing to the development of the disease are less well defined
for Type 1 Diabetes than for Type 2 Diabetes, but autoimmune, genetic, and
environmental factors are involved in the development of this type of
Diabetes.
2. Type 2 Diabetes was previously called Non-Insulin-Dependent
Diabetes Mellitus or Adult-Onset Diabetes. The CDC estimates that Type 2
Diabetes may account for about 90% to 95% of all diagnosed cases of Diabetes.
Factors associated with Type 2 Diabetes include age, obesity, family history
of Diabetes, prior history of Gestational Diabetes, impaired glucose
tolerance, physical inactivity, and ethnicity. According to the CDC, African
Americans, Hispanic or Latin Americans, American Indians, and some Asian
Americans and Pacific Islanders are at particularly high risk for Type 2
Diabetes.
3. Gestational Diabetes develops in 2% to 5% of all pregnancies,
according to the CDC, but disappears when a pregnancy is over. The CDC also
reports that Gestational Diabetes occurs more frequently in African
Americans, Hispanic/Latin Americans, American Indians, and persons with a
family history of diabetes. Obesity also increases the risk of Gestational
Diabetes. Women who have a history of Gestational Diabetes are at increased
risk for later developing Type 2 Diabetes. According to the CDC, some studies
have found that nearly 40% of women with a history of Gestational Diabetes
developed Diabetes in the future.
4. "Other specific types" of Diabetes result from specific
genetic syndromes, surgery, drugs, malnutrition, infections, and other
illnesses. The CDC reports that such types of Diabetes may account for 1% to
2% of all diagnosed cases of Diabetes.
PREVALENCE OF DIABETES IN THE UNITED STATES. In a release dated
November 1, 1998, the CDC estimated that 15.7 million people in the United
States, or 5.9% of the population, had Diabetes and that approximately
798,000 new cases of Diabetes are diagnosed each year. The cases were
segmented as follows:
Total (diagnosed and undiagnosed): 15.7 million, Diagnosed: 10.3
million, Undiagnosed: 5.4 million, Type 1 Diabetes: 1 million Type 2 Diabetes:
14.9 million Women: 8.1 million (8.2% of all adult women) Men: 7.5 million
(8.2% of all adult men) Children age 19 years or younger: 123,000 (.16% of
all people in this age group) Adults age 65 years or older: 6.3 million
(18.4% of all people in this age group)
The distribution of Diabetes among adults, reported by race and
ethnicity (diagnosed and undiagnosed), is as follows: African Americans,
10.8%; Mexican Americans, 10.6%; White Americans, 7.8%; American Indians and
Alaska Natives, 9%.
<PAGE>
According to the American Diabetes Association, the total cost of
Diabetes in 1997 was estimated to be $98 billion. Direct costs, estimated to
be $44.1 billion in 1997, include costs attributable to medical treatment.
Indirect costs, estimated to be $54 billion in 1997, include costs
attributable to disability and mortality.
Based on death certificate data, the CDC reported that Diabetes
contributed to the deaths of 193,140 persons in 1996. According to the CDC,
however, it is believed that death certificate data under-represents deaths
for which Diabetes is the cause or a contributing factor. Diabetes was the
seventh leading cause of death listed on U.S. death certificates in 1996,
according to CDC's National Center for Health Statistics. Diabetes is the
sixth leading cause of death by disease.
Treatment emphasizes control of blood glucose through blood
glucose monitoring, regular physical activity, meal planning, and attention
to relevant medical and psychosocial factors. In many patients, oral
medications and/or insulin injections are also required for appropriate
glucose control. Treatment of Diabetes is an ongoing process that is planned
and regularly reassessed by the health care team, the person with Diabetes,
and his or her family. Patient and family education are important parts of
the process. Type 1 Diabetes can only be treated with insulin injections.
About 40% of Type 2 Diabetes patients use insulin.
Diabetes can lead to significant long-term complications
especially where the disease has not received proper treatment for long
periods. The following table identifies some of the long-term complications
and contains certain statistical data evidencing the relationship to Diabetes:
<TABLE>
<CAPTION>
Complication Relationship to Diabetes
<S> <C>
Heart disease The American Diabetes Association reports
that heart disease is 2 to 4 times more
common in adults with Diabetes and is
present in 75% of Diabetes-related deaths.
Stroke According to the American Diabetes
Association, the risk of stroke is 2 to 4
times higher in people with Diabetes.
High Blood Pressure The CDC estimates that 60 to 65% of people
with Diabetes have high blood pressure.
Blindness Diabetes is the leading cause of new cases
of blindness among people 20 to 74 years of
age, according to the CDC, and 12,000 to
24,000 new cases of blindness each year are
caused by diabetic retinopathy.
Nerve Disease The CDC reports that about 60 to 70% of
people with Diabetes have mild to severe
forms of diabetic nerve damage (with such
manifestations as impaired sensation or pain
in the feet or hands, delayed digestion of
food in the stomach, carpal tunnel syndrome,
and other nerve problems). Severe forms of
diabetic nerve disease are a major
contributing
<PAGE>
cause of lower extremity amputations.
Amputations More than half of lower limb amputations in
the United States occur among people with
Diabetes according to reports by the CDC.
From 1993 to 1995, the average number of
amputations performed each year among people
with Diabetes was 67,000.
Dental Disease According to the CDC, periodontal disease, a
gum disease that can lead to tooth loss,
occurs with greater frequency and severity
in people with Diabetes. They report one
study which found that 30% of Type 1
Diabetes patients age 19 years or older had
periodontal disease.
Complications of Pregnancy The rate of major congenital malformations
in babies born to women with pre-existing
Diabetes varies from 0 to 5% in women who
receive preconception care to 10% in women
who do not receive preconception care,
according to the CDC. 3% to 5% of
pregnancies among women with Diabetes result
in death of the newborn; this compares to a
rate of 1.5% for women who do not have
Diabetes.
Kidney Disease The American Diabetes Association reports
that Diabetes is the leading cause of kidney
disease, accounting for 40% of new cases.
</TABLE>
<PAGE>
ACQUISITION STRATEGY
In addition to the internal growth of the Company described
above, the Company intends to grow by acquiring additional chronic disease
management companies. Through such acquisitions, the Company intends to
develop or increase its capability to conduct order fulfillment, billing and
collecting, sales, utilization, reporting and other operations for the home
delivery of prescription drugs and disease management products and supplies
to patients nationwide.
DEPENDENCE ON MAJOR CUSTOMERS
The Company depends on the managed care payors with which it has
provider agreements. If any managed care providers with which the Company
does business determine to end their relationships with the Company, and the
Company is not able to secure new relationships, the Company's future
business and operating results could be materially and adversely affected. In
addition, the managed care industry is undergoing substantial consolidation.
In the event payors which currently have provider agreements with the Company
are acquired by payors not associated with the Company, the acquired payor
may elect to terminate its agreement with the Company.
INTELLECTUAL PROPERTY
The Company is in the process of applying for registration of the
service mark "MediQuik" with the United States Patent and Trademark Office.
In an Office Action dated August 30, 1999, the United States Trademark and
Patent Office indicated that they had performed a search and found no similar
registered or pending mark which would bar registration. The Company believes
there will be no material adverse effect on its business if it is not able to
register the name. If the Company's registration is unsuccessful and a
competitor registers the name, the competitor might bring an infringement
action against the Company. If such an infringement action were successful,
the competitor could require the Company to change its name or pay a license
fee for the use of the name. If a competitor were to use the name, the
Company may lose customers who are confused by the similarity of the
Company's name and the name of its competitor.
GOVERNMENTAL REGULATIONS
Numerous state and federal laws and regulations affect the
Company's business and operations. Some of those laws and regulations are
discussed below. The Company believes that it is operating its business in
substantial compliance with all existing legal requirements material to the
operation of its business. There are, however, significant uncertainties
regarding the application of many of these legal requirements. The Company
cannot provide assurance that a regulatory agency charged with enforcement of
any of these laws or regulations will not interpret them differently than the
Company has. The Company cannot guarantee that if an enforcement action is
brought against the Company, that the Company would prevail. In addition,
there are numerous proposed healthcare laws and regulations at the
<PAGE>
federal and state levels, many of which may materially affect the Company's
ability to conduct its business as it is presently conducted or adversely
affect the Company's results of operation.
The Company is unable to predict what additional federal or state
legislation or regulatory initiatives may be enacted in the future relating
to the Company's business or the healthcare industry in general, or what
effect such legislation or regulations may have on the Company. The Company
cannot provide any assurance that federal or state governments will not
impose additional restrictions or adopt interpretations of existing laws that
could have a material adverse effect on the Company's business or results of
operation. The Company believes that its operations are currently subject to
these laws only to a limited extent, however, because the Company's current
customers are managed care payors whose revenue is primarily derived from
private rather than government sources.
ANTI-REMUNERATION LAWS. The Company is subject to federal and
state anti-remuneration laws, such as the Medicare/Medicaid anti-kickback
laws, which govern certain financial arrangements among health care providers
and others who may be in a position to refer or recommend patients to such
providers. These laws prohibit, among other things, direct and indirect
payments that are intended to induce the referral of patients to, the
arranging for services by, or the recommending of, a particular provider of
health care items or services. The Medicare/Medicaid anti-kickback law has
been broadly interpreted to apply to certain contractual relationships
between health care providers and sources of patient referral. State laws
vary from state to state, are sometimes vague and seldom have been
interpreted by courts or regulatory agencies. Violation of these laws can
result in civil and criminal penalties, and exclusion of health care
providers or suppliers from participation in (i.e., furnishing covered items
or services to beneficiaries of) the Medicare and Medicaid programs.
BILLING REGULATION. Certain provisions in the Social Security Act
authorize penalties, including exclusion from participation in Medicare and
Medicaid, for various billing-related offenses. The Department of Health and
Human Services can also initiate permissive exclusion actions for improper
billing practices such as submitting claims "substantially in excess" of the
provider's usual costs or charges, failure to disclose ownership and
officers, or failure to disclose subcontractors and suppliers.
FEDERAL AND STATE ASSISTANCE PROGRAMS. Funds received by the
healthcare providers under Medicare and Medicaid are subject to audit with
respect to the proper application of various payment formulas. Such audits
can result in retroactive adjustments of revenue from these programs,
resulting in either amounts due to the government agency from the provider or
amounts due the provider from the government agency. The Company does not
currently receive payments under any Medicare or Medicaid program, but it may
elect to engage in such business in the future.
ENVIRONMENTAL LAWS. Certain federal and state laws govern the
handling and disposal of medical, infectious and hazardous waste. Although
MediQuik sells and supplies products that could be deemed medical, infectious
or hazardous waste after use by the patient, the Company is not involved in
the handling or disposal of such materials after use by patients.
<PAGE>
Further, the Company does not manufacture products, own real property, or
engage in activities which involve hazardous materials, result in the
discharge of pollutants into the environment or are likely to result in the
violation of any existing environmental rules and/or regulations.
Consequently, the Company believes it is in compliance with federal, state
and local laws and regulations regarding environmental matters that may be
applicable to it, if any. To date, the Company has not incurred any material
costs in complying with such laws and regulations and does not anticipate
that costs of compliance with such regulations will have a material affect on
its future expenditures, earnings or competitive position.
EMPLOYEES AND CONSULTANTS
As of March 31, 2000, the Company and its subsidiaries had
approximately 13 full-time employees. The employees of the Company are not
subject to collective bargaining agreements and management believes relations
with employees are good. As of March 31, 2000, the Company also pays four
full-time consultants.
ITEM 2. DESCRIPTION OF PROPERTY
The Company's executive and administrative offices are located at
4295 San Felipe, Suite 200, Houston, Texas 77027, which facilities are leased
by the Company from an unaffiliated third party. The Company's lease covers
3,820 square feet and expires on June 30, 2004. The monthly rental rate for
such premises is $5,252.50. As of March 1, 2000, the Company leased an
additional 1,844 square feet in the basement of the same premises for a
rental amount of $1,950.00 per month. In total, the Company occupies 5,664
square feet in the 4295 San Felipe building. Because services related to many
of the Company's business activities are provided by contractors or
consultants rather than Company employees, the Company requires only limited
office space and facilities for its operations. The Company believes that the
current facilities are adequate for its present needs. Furthermore, the
Company believes that suitable additional or replacement space will be
available when required on terms acceptable to the Company. The Company has
no present intent to invest in real estate, real estate mortgages or persons
primarily engaged in real estate activities; however the Company may change
this policy at any time without a vote of security holders. The Company has
obtained insurance to cover certain risks related to the premises as required
by the terms of the lease.
<PAGE>
ITEM 3. LEGAL PROCEEDINGS
Neither the Company, nor any of its subsidiaries or any of its
properties is a party to any legal proceedings that are not routine
litigation incidental to the business.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted during the fourth quarter of the 1999
fiscal year to a vote of security holders.
PART II.
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
As yet the Company's Common Stock has experienced limited trading
activity. A public trading market having the characteristics of depth,
liquidity and orderliness depends upon the existence of market makers as well
as the presence of willing buyers and sellers, which are circumstances over
which the Company does not have control. Although previously listed on the
NASD Over the Counter Bulletin Board (OTCBB), at present the Company's Common
Stock is listed publicly on the National Quotation Bureau's Pink Sheets under
the Symbol "MDQK". The following table sets forth the high and low sale prices
for the Common Stock (as reported by the Pink Sheets) for the periods
indicated since the inception of trading in January 1999. The quotations
below reflect inter-dealer prices, without retail mark-up, mark-down or
commission, and may not represent actual transactions.
<TABLE>
<CAPTION>
Period High Low
- ------ ------ -----
<S> <C> <C>
First Quarter (from January 26, 1999
through March 31, 1999) $4.625 $1.75
Second Quarter $7.875 $3.125
Third Quarter $4.50 $1.125
Fourth Quarter (from October 1, 1999
to October 8, 1999) $2.00 $1.50
</TABLE>
On December 6, 1999 the last reported sales of the Common Stock
on the OTCBB was $2.50. As of March 31, 2000, there were 148 holders of
record of the Common Stock, as shown on the records of the Transfer Agent and
Registrar of the Common Stock. Since many shares may be held by investors in
nominee names, such as the name of their broker or their broker's nominee,
the number of record holders often bears little relationship to the number of
beneficial owners of the Common Stock.
The Company has never paid any cash dividends on its stock and
anticipates that for the foreseeable future it will retain earnings, if any,
for use in the operation of its business.
<PAGE>
Payments of cash dividends in the future will depend upon the Company's
earnings, financial condition, any contractual restrictions, restrictions
imposed by applicable law, capital requirements and other factors believed
relevant by the Company's Board of Directors.
In December 1999, the Company through certain officers acting on its
behalf, began selling unregistered securities through a private placement for
a maximum offering of $6,000,000. The price per unit is $2.00, and each
unit consists of one share of common stock and a warrant to purchase two
shares of common stock. As of December 31, 1999 MediQuik had raised $215,000
in cash from this offering. The units are being offered in reliance on the
exemption from registration provided by Rule 506 of Regulation D as promulgated
by the SEC.
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
FORWARD LOOKING STATEMENTS
This management discussion contains certain forward-looking
statements as identified by the use of words like "expects", "believes", and
"anticipates" and other similar phrases. Such statements reflect management's
current view of future financial performance based on certain assumptions,
risks and uncertainties. If any assumptions, risk or uncertainty factors
change, such changes may have a material impact on actual financial results.
The Company is under no obligation to revise any forward-looking statements
contained herein, which are as of the date hereof. Readers are cautioned to
not place undue reliance on any forward-looking statements contained in this
discussion.
OVERVIEW
MediQuik is a healthcare services company specializing in the
delivery of chronic disease management programs to chronically ill patients
on behalf of managed care payors.
The Company's business was organized on April 7, 1998, and began
full-time operations in July 1998 as Old MediQuik. Effective December 31,
1998, Old MediQuik merged with and into Cash Flow Marketing, Inc., with Cash
Flow as the surviving corporation. Cash Flow changed its name to MediQuik
Services, Inc. immediately following the merger. This transaction has been
treated as a capital transaction in substance rather than a business
combination; thus, the accounting is similar to a reverse acquisition but no
goodwill and/or intangibles have been recorded. As a result Old MediQuik is
considered the accounting acquirer for financial statement purposes.
Therefore, the financial statements of the Company for periods prior to
January 1, 1999 are the financial statements of Old MediQuik, not Cash Flow
Marketing, Inc.
Although initial Company revenues were derived primarily through
product sales, the Company has expanded beyond product delivery and has
become a full disease management provider working to improve patient care and
reduce costs to managed care payors. The Company currently offers managed
care agreements based on fee-for-service and capitated fee arrangements.
The Company is currently serving patients with Diabetes and is
developing new disease management programs for other high cost, chronic
diseases, such as asthma and congestive heart failure. MediQuik is focusing
on certain diseases with large afflicted patient populations where clinical
research indicates that active management will improve the health condition
of the patient and reduce the financial burden for managed care payors. The
Company is in the process of conducting research regarding the new disease
management programs.
<PAGE>
MediQuik offers comprehensive disease monitoring and maintenance
solutions by providing pharmacy and diagnostic products, disease education,
adherence review and reporting, and personal health resources via the U.S.
Mail, telephone and the Internet. The Company provides a complete line of
blood glucose monitoring systems, testing strips, lancets, swabs, insulin
pumps, compliance and wound care products for diabetes patients, and the
Company is adding new products and services to complement existing disease
management programs. MediQuik is focused on delivering high quality products
and services to chronic disease patients for insurance organizations that
bear the primary financial risk for healthcare treatment. MediQuik also works
directly with health maintenance organizations (HMOs), preferred provider
organizations (PPOs), self-insured companies and other third-party payors
(TPAs) in an effort to enhance the quality of life for chronically ill
patients and improve the financial outcomes for managed care payors. The
Company also provides billing and collection activities on behalf of the
patient to the healthcare plan.
Research indicates that patients who actively manage certain chronic
disease factors experience reduced disease complications and an enhanced
quality of life. The Company believes that a coordinated disease management
program, including convenient product delivery and billing, personalized
patient education, routine disease counseling, immediate access to healthcare
professionals, and ongoing compliance testing will improve clinical and
financial outcomes for patients and managed care payors.
LIQUIDITY AND CAPITAL RESOURCES
The Company's principal cash requirements to date have been to fund
working capital in order to support growth of net sales. Because revenue from
operations has been inadequate to completely fund these requirements, the
Company has supplemented its revenue from operations with proceeds from its
private offerings of securities, loans and extensions of credit from vendors
in order to meet its working capital requirements. The Company anticipates
that as revenue from sales to managed care plans increases, the Company will
be able to satisfy all of its funding requirements for operations from such
revenue. The Company had an aggregate of $47,424 in cash as of December 31,
1999.
The Company has $130,000 of 15% Subordinated Debentures originally
due in June and December 1999. The Company paid $15,000 of the debentures in
July 1999, $55,000 in December 1999, and $10,000 in March,1999 and has
received an extension on the balance of $50,000, plus accrued interest, until
June 2000. The debentures are owed to significant shareholders of the
Company. The Company has accrued wages of approximately $178,000 primarily to
Company officers and insiders who are significant shareholders in the
Company. The Company expects to pursue additional equity and debt financing
to meet future working capital requirements.
Accounts receivables are primarily derived from payments due to the
Company by managed care plans and providers. As revenues increase, the
Company expects working capital requirements to increase. Standard medical
billing cycles for managed care plans
<PAGE>
average between 45-60 days. The Company expects to experience similar billing
cycles as direct managed care plan business increases.
In July 1999, the Company obtained a verbal agreement to provide up
to $100,000 of credit so long as an officer of the Company maintains
sufficient compensating balances in accounts with the lender. Pursuant to
this arrangement, R. Craig Christopher, Chief Operating Officer of the
Company, deposited $100,000 with First Bank Texas N.A. ("First Bank") and
transferred $35,000 to the Company's account, which the Company subsequently
repaid to Mr. Christopher without interest. Mr. Christopher currently
maintains a $100,000 compensating balance with First Bank to support the
Company's liquidity needs. Neither First Bank nor Mr. Christopher have made
any commitment to continue this practice, and it could be terminated by
either First Bank or Mr. Christopher at any time.
In December 1999, the Company began raising money from private
investors through a Private Placement Memorandum. As of December 31, 1999,
MediQuik has raised $215,000 in cash. The PPM established a unit price of
$2.00 per unit. The unit includes one share of MediQuik common stock and two
warrants to purchase a share of common stock exercisable at $2.00 per share.
Pursuant to an asset purchase agreement with Scardello Marketing
Group, LLC ("SMG") in July 1999, the Company assumed a Commercial Revolving
or Draw Note, dated May 19, 1999, in the original principal amount of $25,000
executed by SMG for the benefit of First Bank and with a maturity date of
June 5, 2001. The outstanding principal amount of the note is currently $0,
which bears interest at a variable rate per annum of 1.5% over the prime rate
as quoted and adjusted by First Bank. The Company expects to seek additional
lines of credit to finance inventory purchase requirements associated with
revenue growth.
On March 31, 2000, MediQuik signed a Letter of Intent with MiraQuest
Capital Holdings, Inc (MiraQuest). The terms of Letter of Intent provide
MediQuik with $2,000,000 in initial funding and an equity interest in
MiraQuest, an Internet Holding Company comprised primarily of
business-to-business entities. As of the date of this filing, MediQuik has
received $300,000 in advances pursuant to the terms of the Letter of Intent.
MiraQuest has a stated value of $400,000,000. MediQuik is being valued at
approximately $13,000,000 ($2.00 per share). The transaction would provide
MiraQuest with 70%-80% of the voting stock in MediQuik. MediQuik has engaged
the financial advisory firm of Howard, Frazier, Barker, Elloitt, Inc. to
provide a fairness opinion on the transaction. MiraQuest has several healthcare
internet holdings including Everfill.com, JITMedical,com and Seniorcities.com.
RESULTS OF OPERATIONS
MediQuik is rapidly expanding through internal sales growth and
plans to conduct strategic acquisitions to further fuel growth and accelerate
the time to market of additional planned services. During 1998 and 1999, the
Company established: (i) corporate marketing and fulfillment operations; (ii)
contractual relationships with product manufacturers; (iii) contractual
relationships with specialty service providers; (iv) contractual
relationships with
<PAGE>
insurance payors and provider networks; (v) contractual relationship with a
pharmacy products distribution company; and (vi) initial patient enrollment
and fulfillment operations.
During 1999, the Company expanded its sales efforts, signing 6 new
diabetes management contracts.
REVENUE FROM OPERATIONS
The Company commenced operations in July 1998 and received its
initial revenue in August 1998. For the period from April 7, 1998 to December
31, 1998, the Company reported revenue of $372,226. Total revenue increased
to $982,292 for the 12 months ended December 31, 1999.
Revenue growth was primarily derived from diagnostic product sales
to managed care plans, providers and patients. The Company is currently
deriving the majority of its revenues through direct sales to managed care
plans. The Company expects to realize significant improvement in gross margin
percentages with increased direct managed care plan revenues. Cash flow from
operations has not been sufficient to fund all of the Company's initial
operating activities to date.
MediQuik receives patients primarily through agreements with managed
care plans and provider networks. Management believes that enrollment in
managed care plans has increased in recent years and, as a result, patient
referrals generated through the managed care plans should increase.
GROSS PROFIT
The Company commenced operations in July 1998 and received its
initial gross profit in August 1998. For the period from April 7, 1998 to
December 31, 1998, the Company reported gross profit of $54,673 or 14.7% of
revenue for the period. Gross profit increased to $257,687 or 26.2% of
revenue, for the 12 months ended December 31, 1999.
Gross profit was derived from diagnostic product sales to managed
care payors and patients. The gross profit percentage is the result of volume
purchase discounts. The Company expects continued increases in gross profit
percentage with increased direct sales to managed care plans.
OPERATING EXPENSES
For the period from April 7, 1998 to December 31, 1998, operating
expenses were $856,532. Operating expenses increased to $3,380,248 for the 12
months ended December 31, 1999, an increase of 295%. The increase in
operating expenses is primarily associated with the initiation of operating
business activities including marketing and selling expenses, general and
administrative costs, consultant's compensation and the hiring and training
of staff. Operating expenses include the effect of $1,508,742 in several
non-cash equity transactions.
<PAGE>
NET LOSS
The Company experienced a net loss of $829,854 for 1998, primarily
attributed to the development of the Company's business operations. Net loss
increased to $3,129,659 for the 12 months ended December 31, 1999. Net Loss
includes the effect of $1,508,742 in several non-cash equity transactions.
The Company expects the net loss to decrease with increased revenues and
gross profits from business operations.
ITEM 7. FINANCIAL STATEMENTS
INDEPENDENT AUDITORS' REPORT
To the Board of Directors and Stockholders of
MediQuik Services, Inc.
Houston, Texas
We have audited the accompanying consolidated balance sheets of
MediQuik Services, Inc. and subsidiary (the "Company") as of December 31,
1999 and 1998, and the related consolidated statements of operations, changes
in stockholders' equity (deficit), and cash flows for the year ended December
31, 1999 and for the period from April 7, 1998 (date of incorporation) to
December 31, 1998. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards
generally accepted in the United States of America. Those standards require
that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by management, as
well as evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present
fairly, in all material respects, the financial position of the Company as of
December 31, 1999 and 1998, and the results of their operations and their
cash flows for the year ended December 31, 1999 and for the period from April
7, 1998 (date of incorporation) to December 31, 1998 in conformity with
accounting principles generally accepted in the United States of America.
/s/ DELOITTE & TOUCHE
Houston, Texas
April 5, 2000
<PAGE>
MEDIQUIK SERVICES, INC.
CONSOLIDATED BALANCE SHEETS
- -------------------------------------------------------------------------------
<TABLE>
<CAPTION>
December 31, December 31,
1999 1998
------------------------------
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 47,424 $ 7,578
Accounts receivable, net of allowance of $88,702
and $0, respectively 141,695 50,785
Advances - 16,000
Inventory 21,737 79,093
----------- --------
Total current assets 210,856 153,456
PROPERTY AND EQUIPMENT:
Office equipment 74,850 249
Less accumulated depreciation (7,215) (29)
----------- --------
Total property and equipment 67,635 220
GOODWILL AND OTHER ASSETS 1,140,527 61,651
----------- --------
TOTAL $ 1,419,018 $215,327
=========== ========
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable $ 199,479 $153,656
Accrued expenses 598,208 100,908
Notes payable and subordinated debentures 85,000 280,000
----------- --------
Total current liabilities 882,687 534,564
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock - 1,000,000 shares authorized, none
issued and outstanding
Common stock - $.001 par value 25,000,000 shares
authorized; 6,032,007 shares issued and outstanding
at December 31, 1999 and 4,849,173 shares issued and
outstanding at December 31, 1998 6,033 4,849
Additional paid-in capital 4,489,811 505,768
Accumulated deficit (3,959,513) (829,854)
----------- --------
Total stockholders' equity (deficit) 536,331 (319,237)
----------- --------
TOTAL $ 1,419,018 $215,327
=========== ========
</TABLE>
See accompanying notes to financial statements.
<PAGE>
MEDIQUIK SERVICES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Year Period from
Ended April 7, 1998 to
December 31, December 31,
1999 1998
-----------------------------------
<S> <C> <C>
SALES $ 982,292 $ 372,226
COST OF SALES 724,605 317,553
----------- ----------
GROSS PROFIT 257,687 54,673
OPERATING EXPENSES:
Salaries - officers 412,323 138,000
Consulting fees 1,613,590 433,712
Other 1,354,335 284,820
----------- ----------
Total operating expenses 3,380,248 856,532
----------- ----------
LOSS FROM OPERATIONS (3,122,561) (801,859)
OTHER INCOME (EXPENSE):
Interest income 3,048 315
Other income 14,114 -
Interest expense (24,260) (28,310)
----------- ----------
Total other (expense) income (7,098) (27,995)
----------- ----------
NET LOSS $(3,129,659) $ (829,854)
=========== ==========
BASIC AND DILUTED LOSS PER SHARE $ (0.57) $ (0.21)
=========== ==========
BASIC WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING 5,537,900 3,934,409
=========== ==========
DILUTED WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING 5,540,589 3,934,409
=========== ==========
</TABLE>
See accompanying notes to financial statements.
<PAGE>
MEDIQUIK SERVICES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) FOR THE
YEAR ENDED DECEMBER 31, 1999 AND THE PERIOD FROM APRIL 7, 1998 (DATE OF
INCORPORATION) TO DECEMBER 31, 1998
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Additional
Common Paid-In Accumulated
Shares Stock Capital Deficit Total
----------------------------------------------------------
<S> <C> <C> <C> <C> <C>
BALANCE, APRIL 7 1998 (Date of Incorporation)
Proceeds from issuance of Founders' shares 110,000 $ 110 $ 110
Acquisition of MediQuik Services LLC assets 2,750,000 2,750 2,750
Proceeds from issuance of warrants $ 11,000 11,000
Issuance of warrants for consulting services 117,961 118 235,922 236,040
Issuance of restricted stock 1,000,000 1,000 1,000
Conversion of Convertible Debt 75,000 75 2,925 3,000
Acquisition of Cash Flow Management Inc. 662,165 662 662
Proceeds from exercise of warrants and
issuance of common stock 134,047 134 255,921 256,055
Net loss $(829,854) (829,854)
--------- ------ --------- --------- ---------
BALANCE, DECEMBER 31, 1998 4,849,173 4,849 505,768 (829,854) (319,237)
Repurchase of unexercised warrants (12,880) (12,880)
Proceeds from issuance of common stock 570,500 571 1,167,030 1,167,601
Issuance of common stock under consulting
agreements 272,334 273 1,017,169 1,017,442
Issuance of warrants for consulting services 463,100 463,100
Issuance of common stock under employment
agreement 10,000 10 28,190 28,200
Acquisition of Scardello Marketing Group LLC
assets 330,000 330 1,237,170 1,237,500
Proceeds received for interest in subsidiary 84,264 84,264
Net loss (3,129,659) (3,129,659)
--------- ------ ---------- ------------ ----------
BALANCE, DECEMBER 31, 1999 6,032,007 $6,033 $4,489,811 $(3,959,513) $ 536,331
========= ====== ========== ============ ==========
</TABLE>
See accompanying notes to financial statements.
<PAGE>
MEDIQUIK SERVICES, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Year Period from
Ended April 7, 1998 to
December 31, December 31,
1999 1998
-------------------------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss (3,129,659) $ (829,854)
Adjustment for noncash transactions:
Common stock and warrants issued for services 1,508,742 240,040
Depreciation and amortization 139,879 9,141
Provision for losses on accounts receivable 88,702 -
Net changes in assets and liabilities:
Accounts receivable (179,612) (50,785)
Advances - (16,000)
Inventory 57,356 (79,093)
Accounts payable 45,823 153,656
Accrued expenses 497,300 100,908
Other assets 52,630 (70,763)
Other (10,699) -
----------- -----------
Net cash used in operating activities (929,538) (542,750)
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES -
Capital expenditures (74,601) (249)
----------- -----------
Net cash used in investing activities (74,601) (249)
----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt issuance 25,000 280,000
Repayment of indebtedness (220,000) -
Repurchase of unexercised warrants (12,880) -
Proceeds from sale of common stock 1,167,601 270,577
Proceeds from sale of interest in subsidiary 84,264 -
----------- -----------
Net cash provided by financing activities 1,043,985 550,577
----------- -----------
NET INCREASE IN CASH 39,846 7,578
CASH, beginning of period 7,578 -
----------- -----------
CASH, end of period $ 47,424 $ 7,578
=========== ===========
SUPPLEMENTAL CASH FLOW DISCLOSURES
Interest paid $ 26,365 $ -
NONCASH TRANSACTIONS
Restricted stock award $ - $ 1,000
Debt converted to stock - 3,000
Stock issued in MediQuik Services LLC acquisition - 2,750
Acquisition of Scardello Marketing Group assets 1,237,500 -
</TABLE>
See accompanying notes to financial statements.
<PAGE>
MEDIQUIK SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED DECEMBER 31, 1999 AND FOR THE PERIOD
FROM APRIL 7, 1998 (DATE OF INCORPORATION) TO DECEMBER 31, 1998
- --------------------------------------------------------------------------------
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND BUSINESS ACTIVITY - MediQuik Services, Inc.
("MediQuik") was organized in Delaware on April 7, 1998. On April 7, 1998,
MediQuik issued an aggregate of 2,750,000 shares of its common stock to
designees of MediQuik Services, LLC in consideration of the transfer of certain
assets of MediQuik from MediQuik Services, LLC. Effective December 31, 1998,
MediQuik was merged with and into Cash Flow Marketing, Inc., a Delaware
corporation ("Cash Flow"), which, as the surviving corporation, subsequently
changed its name to MediQuik Services, Inc. (the "Company"). This transaction
has been treated as a capital transaction in substance, rather than a business
combination; thus the accounting is similar to a reverse acquisition but no
goodwill and/or intangible has been recorded. As a result, MediQuik is
considered the acquiring entity for financial statement purposes, and the
financial statements for the period prior to January 1, 1999 are those of
MediQuik Services, Inc, not Cash Flow, the legal acquirer.
In connection with the merger, the Company issued an aggregate of
4,849,000 shares of common stock to the stockholders of MediQuik and Cash Flow.
At the time of the merger, Cash Flow was a "Shell" corporation with
substantially no assets, business or operations.
PRINCIPLES OF CONSOLIDATION - The accompanying consolidated financial
statements include the accounts of MediQuik Services, Inc. and its subsidiary
ChronicRX.com (collectively, the "Company"). All significant intercompany
accounts and transactions have been eliminated.
USE OF ESTIMATES - The preparation of the accompanying consolidated
financial statements in conformity with generally accepted accounting principles
requires management to make certain estimates and assumptions that directly
affect the results of reported amounts of assets, liabilities, revenues, and
expenses. Actual results may differ from these estimates.
REVENUE AND COST RECOGNITION - The Company generates revenue from
provider agreements by delivering medical supplies directly to patients covered
by these provider agreements. The Company recognizes revenues from sales
contracts when products are shipped. The Company has not experienced any product
returns to date.
INVENTORY - Inventory consists of chronic disease management products
and is reflected in the consolidated financial statements at the lower of cost
(first in first out) or market.
CASH AND CASH EQUIVALENTS - Cash and cash equivalents for purposes of
these consolidated financial statements are considered to be all highly liquid
debt instruments with an original maturity of three months or less.
<PAGE>
BAD DEBTS - An allowance for bad debts provided for based on
management's best estimates of amounts that are deemed uncollectible. Such
allowance is $88,702 and $0 at December 31, 1999 and 1998, respectively.
PROPERTY AND EQUIPMENT - Property and equipment is stated at cost. The
cost of betterments are added to the property accounts. Maintenance and repair
costs are charged to expenses as incurred. Upon disposal of an asset, the
difference between the sales proceeds and the net book value is charged or
credited to income. The Company follows the American Institute of Certified
Public Accountants Statement of Position No. 98-1, "Accounting for Costs of
Computer Software Developed or Obtained for Internal Use" to determine when to
capitalize or expense costs incurred to develop or obtain internal use
software, such as the internet site. Under this guidance, the Company
expenses costs incurred in the preliminary project stage and thereafter
capitalizes costs incurred in developing or obtaining internal use software.
Certain costs, such as licensing, maintenance and training, are expensed as
incurred. Depreciation of property is provided using primarily the straight-line
method over the following estimated useful lives:
<TABLE>
<CAPTION>
Classification Years
<S> <C>
Internet site 3
Office equipment 5
Furniture and fixtures 7
</TABLE>
Depreciation expense was $7,186 and $29 for the year ended December 31,
1999 and the period from April 7, 1998 to December 31, 1998, respectively.
GOODWILL AND OTHER ASSETS - The cost over the fair value of net assets
acquired (goodwill) is amortized by the straight-line method over five years. At
December 31, 1999, goodwill amounted to $997,120 (net of accumulated
amortization of $110,791).
As a result of the purchase of assets from MediQuik Services, LLC,
the Company has recorded an identified intangible in other assets related to
certain contracts acquired. This intangible ceased to be of value to the
Company during 1999 and an impairment of $52,539 has been recognized in the
1999 consolidated statements of operations. As of December 31, 1998, the
accumulated amortization is $9,112.
The Company reviews goodwill and intangible assets on a quarterly
basis to determine if such intangibles have been impaired. Any impairment
would be recognized in the statement of operations.
SIGNIFICANT CUSTOMERS- The Company had sales to five significant
customers of approximately 87% for the year ended December 31, 1999 and to a
single significant customer of approximately 86% for the period ended December
31, 1998. Such customers represented approximately 80% of the accounts
receivable balances at December 31, 1999 and 1998.
COMPREHENSIVE INCOME - In June 1997 the Financial Accounting Standards
Board issued Statement of Financial Accounting Standards No. 130, "Reporting of
Comprehensive Income" ("SFAS 130"). SFAS 130 establishes standards for reporting
and displaying comprehensive income and its components. SFAS 130 is effective
for periods beginning after December 31, 1997. The purpose of reporting
comprehensive income is to report a measure of all changes in equity of an
enterprise that results from recognized transactions and other economic events
of the period other than transactions with owners in their capacity of owners.
As of December 31, 1999 and 1998, there are no adjustments ("Other Comprehensive
Income") to net loss in deriving comprehensive income.
SEGMENT DISCLOSURES - In June 1997 the Financial Accounting Standards
Board issued Statement of Financial Accounting Standards No. 131, "Disclosures
About Segments of an Enterprise and Related Information" ("SFAS 131"). SFAS 131
establishes standards for the way that public business enterprises report
information about
<PAGE>
operating segments. SFAS 131 is effective for periods beginning after December
31, 1997. The Company currently operates under one segment.
DERIVATIVES - In June 1998 the Financial Accounting Standards Board
("FASB") issued Statement of Financial Accounting Standards No. 133, "Accounting
for Derivative Instruments and Hedging Activities" ("SFAS 133"), which
establishes accounting and reporting standards for derivative instruments and
hedging activities. In June 1999 FASB issued SFAS No. 137, which delays the
effective date for implementation of SFAS 133 to fiscal years beginning after
June 15, 2000. The Company held no derivatives in 1999 or 1998 and believes that
SFAS No. 133, when adopted effective January 1, 2001, will not materially impact
its financial position or results of operations.
FAIR VALUES OF FINANCIAL INSTRUMENTS - At December 31, 1999 and 1998,
the carrying amounts of the Company's cash, receivables and payables
approximated their fair values.
2. EARNINGS PER SHARE
The Company has adopted SFAS 128, "Earnings per Share," which
establishes standards for computing and presenting earnings per share ("EPS").
SFAS 128 requires the presentation of "basic" and "diluted" EPS on the face of
the consolidated statement of operations. Basic EPS amounts are calculated
using the average number of common shares outstanding during each period.
Diluted earnings per share assumes the exercise of all stock options and
warrants having exercise prices less than the average market price of the
common stock using the treasury stock method. No dilutive securities of the
Company were outstanding at December 31, 1998; however, warrants to purchase
250,000 shares of common stock at exercise prices ranging from $3.00 - $4.00
per share were issued from February to April 1999. In addition, in connection
with the sale of certain common stock during 1999, the Company issued warrants
to purchase 215,000 shares of common stock at an exercise price of $2.00. Since
the Company incurred a loss for all periods presented, any dilutive securities
would have been excluded, as they would be anti-dilutive to basic EPS.
3. ACQUISITIONS
The Company entered into an agreement to purchase certain assets of
Scardello Marketing Group, LLC ("SMG") on June 18, 1999; this acquisition was
effective and was closed July 1999. The Company acquired the Exclusive Marketing
Representative Agreement ("Marketing Agreement") between SMG and the Company
with a term of five years ending in 2004, acquired certain computer equipment,
and acquired all documents, materials, target lists, customer lists, and
receivables, if any, derived from the Marketing Agreement. The Company also
assumed a note payable of $25,000 due to a bank but also received the proceeds
of such note.
In connection with the acquisition of SMG's assets during July 1999,
330,000 shares of common stock were issued to SMG and the Company forgave
$15,396 in debt due from SMG. The Company acquired the assets of SMG primarily
to obtain rights to the Marketing Agreement and services of the principal of SMG
to further internally
<PAGE>
develop the Company's business.
The allocation of purchase price is summarized as follows:
<TABLE>
<S> <C>
Total purchase price $1,256,896
==========
Amount allocated to book value of net assets acquired at cost 3,000
Amount allocated to intangibles (amortized over 5 years) $1,253,896
----------
Total recorded amount of purchased assets $1,256,896
==========
</TABLE>
4. SUBSIDIARIES
In May 1999, MediQuik formed an 80% owned subsidiary known as
ChronicRX.com to provide Internet-based pharmacy services. ChronicRX.com will
focus on the chronic care niche and will specialize in prescription and
non-prescription medicines and management products used to treat chronic
diseases of all kinds.
ChronicRX.com has a net loss of approximately $139,500 for the year
ended December 31, 1999 and has a deficiency in net assets. Accordingly, the
Company has not recognized a liability to the minority interest.
The Company anticipates that ChronicRX.com will become a wholly-owned
subsidiary of the Company. In March 2000, the Company reached agreements
with investors who have contributed cash to ChronicRX.com to exchange their
interest in ChronicRX.com for shares of the Company at $1.75 per share.
5. INCOME TAXES
The Company has a net operating loss carryforward of approximately
$2,730,000 and $734,000 as of December 31, 1999 and 1998, respectively, that
may be applied against future federal taxable income. This loss gives rise to
a deferred tax asset at December 31, 1999 and 1998 of approximately $928,000
and $249,000, respectively. Management has established a valuation allowance
equal to the amount of the deferred tax asset, as it is more likely than not
that the Company will not be able to realize this asset. The loss
carryforward begins to expire on December 31, 2018.
<PAGE>
6. NOTES PAYABLE
Notes payable and subordinated debentures consist of the following:
<TABLE>
<CAPTION>
December 31, December 31,
1999 1998
<S> <C> <C>
Note payable to bank with variable interest rate at 1.5% over
Prime, due June 5, 2001 $ 25,000 $ -
Three notes payable, $50,000 each to shareholders with interest
at 9%, payable February 20, 1999 - 150,000
Subordinated debentures payable to shareholders with interest at
15%, payable in two installments of $15,000 each, due on June 30,
1999 and December 31, 1999 - 30,000
Ten subordinated debentures payable, $10,000 each to certain
shareholders with interest at 15%, due on June 30, 1999 and
December 31, 1999 60,000 100,000
--------- --------
$ 85,000 $280,000
========= ========
</TABLE>
Of the amounts due in June and December, 1999, $220,000 was paid during
1999. The remaining $60,000 payment due on December 31, 1999 has been extended
until June 30, 2000.
In July 1999 the Company obtained a verbal agreement to provide up
to $100,000 of credit so long as an officer of the Company maintains sufficient
compensating balances in accounts with the lender. Repayment of such line of
credit has been guaranteed by the same officer of the Company.
The three 9% notes payable had an original aggregate principal balance
of $153,000. Each of the notes payable provided for $1,000 of the outstanding
principal to be convertible into 25 shares of the Company's common stock for
$1.00 of debt converted. In August 1998 the three note holders each converted
$1,000 of principal into 25,000 shares of common stock.
7. EQUITY TRANSACTIONS
WARRANTS - From February to April 1999, the Company issued new warrants
to purchase 250,000 shares of common stock at an exercise price ranging from
$3.00 to $4.00 per share in consideration for services provided. All warrants
expire by April 30, 2000; the Company has recorded an expense of $463,100 based
on the fair value of the warrants as of the grant date.
In December 1999, in connection with the sale of common stock the
Company issued warrants to purchase 215,000 shares of common stock at an
exercise price of $2.00. The warrants begin to become exercisable in June 2000
and expire in December 2001.
In April 1998 the Company issued warrants for the purchase of 1,100,000
shares of MediQuik common stock at an exercise price ranging from $2.00 to $5.00
per share in consideration of $11,000. Additionally, performance-based warrants
for the purchase of 440,000 shares of common stock were issued to a consultant
at an exercise price of .001 per share; during November 1998, warrants for the
purchase of 117,961 shares of common stock were exercised based on the
performance criteria. The Company has recorded compensation expense of $236,040
based on the fair value of the common stock issued in November 1998.
Following consummation of the Cash Flow merger, the consulting
agreement was amended and all unexercised warrants were repurchased for $12,880.
<PAGE>
PRIVATE STOCK OFFERINGS - In February 1999 the Company issued 350,000
shares of common stock for $700,000.
In June 1999 the Company issued 75,000 shares of common stock for
$150,000.
In July 1999 the Company issued 38,000 shares of common stock for
$102,601.
In December 1999, the Company issued 107,500 shares of common stock
and warrants for $215,000.
From August to October 1998, warrants for the purchase of 134,047
shares of common stock were exercised for $256,055.
OTHER EQUITY TRANSACTIONS - During February to December 1999, the
Company issued 282,334 shares of common stock to various consultants and
employees of the Company at a fair value of approximately $1,024,642.
On April 7, 1998, the Company issued 110,000 shares of common stock for
$110.
On April 15, 1998, the Company granted 1,000,000 shares of common
stock, pursuant to the Company Stock Incentive Plan, to certain key executives
at a value of $.001 determined by the Board of Directors for issuance during
1998.
On April 15, 1998, the Company granted 300,000 non-vested shares of
common stock to a consultant for financial advisory and corporate consulting
services at a value of $.001 determined by the Board of Directors for issuance
by April 14, 1999. Such shares were canceled in connection with the amended
consulting agreement referred to above.
8. RELATED PARTY TRANSACTIONS
As of December 31, 1999 and 1998, the Company had certain outstanding
receivable balances of $0 and $22,865 with related parties and payable balances
of $40,250 and $19,644, respectively. The receivable amounts derive from sales
in the ordinary course of business and the payable amounts relate to certain
consulting services.
During the periods ended 1999 and 1998, the Company paid for business
plan development and investment banking services furnished by an affiliate and
certain consulting and legal services performed by other related parties. During
the periods ended December 31, 1999 and 1998, the Company incurred expenses of
$154,750 and $173,500 for these services, respectively, which are included in
the statement of operations. In addition, the Company has accrued wages of
$178,345 primarily to Company officers who are shareholders of the Company.
9. STOCK INCENTIVE PLAN
The Company completed a Stock Incentive Plan to provide stock
incentives to certain key employees and directors of the Company. An aggregate
of 1,500,000 shares of common stock may be issued pursuant to the Stock
Incentive Plan. See Note 7 for information concerning shares issued in
connection with the stock incentive plan.
10. COMMITMENTS AND CONTINGENCIES
The Company has entered into several provider agreements with various
corporations for terms ranging from one to five years. The Company supplies
diagnostic
<PAGE>
products to the patients under these provider agreements. The Company has also
entered into two consulting agreements containing monthly fees.
LEASE - On May 7, 1999, the Company entered into a new five-year lease
agreement for office space. The minimum lease payments under such agreement are
as follows:
<TABLE>
<CAPTION>
<S> <C>
2000 $ 63,030
2001 63,030
2002 63,030
2003 63,030
2004 31,515
---------
Total $ 283,635
=========
</TABLE>
Rent expense amounted to $55,414 and $29,369 for the periods ended
December 31, 1999 and 1998, respectively. In March 2000, the Company leased
additional office space. The minimum lease payments will increase $23,400 for
each year due to the additional lease payment.
PURCHASE COMMITMENTS - The Company has entered into an agreement with a
supplier of diabetes management products to purchase certain minimum quantities
of product on an annual basis in order to receive specified discounted prices.
LOST SHARE CERTIFICATE - During July 1999, the Company authorized
and issued a certificate for 330,000 shares of common stock to SMG. The
certificate was issued with a restricted legend on the face. As of April 5,
2000 the Company has not been able to locate it. As a result, the Company
placed the certificate on hold with the stock transfer agent immediately upon
realization that the certificate was lost during 1999. The Company authorized
and issued an additional certificate for 330,000 shares of common stock to
SMG. SMG confirms that it received only the second certificate. The Company
does not believe that the shares will ever be located and presented in
exchange for value and accordingly the shares have not been included as
outstanding shares, as of December 31, 1999. The restriction of the shares
and the hold placement with the stock transfer agent are basis for the
Company's opinion. The Company plans to cancel such certificate during 2000.
At December 31, 1999 the fair market value of 330,000 shares was
approximately $680,000. If such shares had been outstanding during 1999 the
basic and diluted loss per share would have been $(0.55).
11. SUBSEQUENT EVENTS
On March 31, 2000, the Company signed a Letter of Intent with
MiraQuest Capital Holdings, Inc. (MiraQuest) to issue to MiraQuest an amount
of common stock equal to the amount of the Company's outstanding stock,
including issuances due certain employees, contractors, consultants and any
unexercised Warrants and Options, just prior to the issuance. The intent is
to convey to MiraQuest a 50% ownership of the common stock of the Company on a
fully diluted basis. At closing MiraQuest will additionally purchase a quantity
of voting preferred stock sufficient to provide MiraQuest with a target of 70%
to 80% ownership. The Letter of Intent allows for convertible debt as an
alternative to or supplement to preferred stock.
In return for the common and preferred stock, MiraQuest will provide
to the Company a minimum of $2 million cash net of any advances and MiraQuest
stock for the remaining sum required to equal the valuation of the Company.
The Company has received $200,000 in advances from MiraQuest as of April 5,
2000 with an additional $200,000 due in two equal weekly distributions. These
advances are in the form of cash loans secured by the Company's common stock
in accordance with the provisions of the current terms of the Company's
private stock offering.
The Company's principal cash requirements to date have been to fund
working capital in order to support growth of net sales. Because revenue from
operations has been inadequate to completely fund these requirements, the
Company has supplemented its revenue from operations with proceeds from its
private offerings of securities, loans and extensions of credit from vendors
in order to meet its working capital requirements. The Company anticipates
that as revenue from sales to managed care plans increases, the Company will
be able to satisfy all of its funding requirements for operations from such
revenue. The Company has received $274,000 from the issuance of 137,000
shares of common stock through April 5, 2000.
*******
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
PART III.
<PAGE>
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS PROMOTERS AND CONTROL PERSONS, COMPLIANCE
WITH SECTION 16(a) OF THE EXCHANGE ACT.
The following table sets forth certain information concerning the
Company's executive officers and directors. The members of the Board of
Directors are divided into three classes, as nearly equal in number as possible.
Generally, members are elected for a three-year term, with the term of one class
expiring each year. Howard B. Butler, Jr. is a Class I director, William J.
Marciniak is a Class II director, and Grant M. Gables is a Class III director.
The term of the Class I director expires at the Company's next annual meeting of
stockholders. The terms of the Class II and Class III directors expire at the
annual meeting of stockholders to be held in 2001 and 2002, respectively. At
each annual meeting of stockholders, directors of the class the term of which
then expires will be elected by the holders of the Common Stock to succeed those
directors whose terms are expiring. Officers are elected annually by, and serve
at the discretion of, the Company's Board of Directors.
<TABLE>
<CAPTION>
Name Age Position
<S> <C> <C>
William Marciniak 49 Interim CEO, Vice President of Marketing and
Director
Grant M. Gables 35 Executive Vice President, COO and Director
Howard B. Butler, Jr. 52 Secretary, Treasurer, Corporate Counsel and
Director
R. Craig Christopher 55 Vice President of Product Fulfillment
Benjamin J. Scardello 45 Vice President of Managed Care Services
Lawrence J. Wedekind 44 Director
Donald Holmquest, MD 61 Health Care Counsel
</TABLE>
WILLIAM J. MARCINIAK has been an officer and director of the Company
since April 7, 1998. Since 1989, Mr. Marciniak has served as an independent
consultant to the health care industry. In such capacity he developed employer
funded employee stock ownership plans for the Mediplex Companies, an infusion
therapy company. In addition, he developed a medical receivables securitization
program for Advacare, Inc., a medical billing company, that was funded by
Prudential and arranged a $100,000,000 private placement for Medical Funding,
Inc. and $100,000,000 credit facility for Home Health Plan, Inc. for the
acquisition of infusion pharmacies. From 1982 to 1989 he was President of
Bankers United Trust and from 1974 to 1982 Regional Manager of International
Bank and Trust. Mr. Marciniak graduated from Southern Illinois University in
1973 with a major in business administration and a minor in mathematics.
GRANT M. GABLES has been an officer and director of the Company
since April 7, 1998. Mr. Gables has served as executive management with three
health care billing and technology companies since January 1995. From March 1997
until June 1998, he was Vice President of Marketing for MediNet EDI Solutions
with responsibility for strategic planning and development of technology for
health care organizations. From
<PAGE>
September 1995 until February 1997, he was Executive Vice President of
Reimbursement Assurance Corporation with responsibility for operations
and sales and emphasis on information delivery technology for health care
groups. From January 1995 until August 1995, Mr. Gables was with Rapid
Reimbursement, Inc. as Chief Operating Officer with responsibility for
installation of medical billing capability and management of claims processing
and medical billing. From March 1994 until December 1994, he was General Partner
of GMG Capital Funding Company with responsibility for investment analysis and
financial planning for health care companies. He was Senior Vice President of
International Trade Exchange, Inc. from May 1992 until March 1994. Mr. Gables
graduated from Texas A & M University in 1987 with a Bachelors of Business
Administration degree with a major in finance and from the University of Houston
in December 1993 with a Masters of Business Administration - Finance with
concentrations in finance and marketing.
HOWARD B. BUTLER, JR. has been an officer and director of the
Company since April 7, 1998. Mr. Butler has been a practicing attorney in
Houston, Texas since 1972 and a sole practitioner since 1986. He is a 1969
graduate of Lamar University, Beaumont, Texas with a Bachelor of Business
Administration in economics and a 1972 graduate of the University of Houston
College of Law.
R. CRAIG CHRISTOPHER has been an officer of the Company since July
1, 1998. His primary responsibilities involve the development of strategic
alliances and distribution channels for MediQuik's health care products and
services. Prior to joining MediQuik, Mr. Christopher held senior level
management positions with a number of health care companies, most notably as
founder and Chairman of the Board of Directors of Taylor Medical, Inc., a
distributor of health supplies ("Taylor"). During his tenure, Taylor expanded
from a single location in Texas to 32 offices in 14 states having 150 sales
representatives and achieved total annual sales of $100 million. While at
Taylor, Mr. Christopher developed methods for marketing medical supplies to
physicians and new training and communications procedures to make the sales
force more responsive. In addition, Mr. Christopher led the development of
strict operating controls for Taylor. Mr. Christopher is a 1966 graduate of Rice
University where he was a scholarship athlete.
BENJAMIN J. SCARDELLO has been an officer of the Company since July
27, 1999. Mr. Scardello has held senior management and officer positions with
both regional and national firms in the retail and health care industries. Prior
to joining MediQuik, he was the founder and President of Scardello Marketing
Group, L.L.C. ("SMG"), which was formed to support the national marketing plans
of MediQuik. Prior to his association with MediQuik, Mr. Scardello served as a
Vice President for FH&R Healthcare Services, Inc., a Houston based information
management company. While at FH&R, he co-developed a series of new healthcare
information technologies designed to help physicians, hospital and insurance
companies improve their ability to manage health care operations under a managed
care reimbursement environment. In the early 1990's, Mr. Scardello founded and
served as President of Triad, a medical billing company with over 200 employees
serving leading healthcare providers throughout the nation.
<PAGE>
LAWRENCE J. WEDEKIND served as Chief Executive Officer of the
Company from September 7, 1999 to his resignation from that position in March
2000. He currently serves the Company as a director. In addition, Mr. Wedekind
serves as President and Chief Executive Officer of IntegraNet Gulf Coast, Inc.,
an independent practice association, and Greater Gulf Health Plan, Inc., a
non-profit occupational medicine network. Mr. Wedekind, has 20 years of
experience in the healthcare industry, including management, marketing and
strategic development both in for-profit and not-for-profit entities. Since
1997, Mr. Wedekind has served as President and Chief Executive Officer of
Greater Gulf Medial Alliance, Inc., a comprehensive healthcare management
service organization. From 1996 to 1997, Mr. Wedekind managed and developed
multiple clinics for William D. Clark, M.D., who currently serves as medical
director of both IntegraNet Gulf Coast and Greater Gulf Health Plan. From 1995
to 1996, Mr. Wedekind served as administrator of Yale Hospital, a 99-bed
hospital located in Houston, Texas which was suffering financial difficulties
prior to Mr. Wedekind's engagement. In 1994, he served as the court-appointed
administrator of Twin Oaks Medical Center, a hospital located in Ft. Worth,
Texas, which was being reorganized under bankruptcy proceedings pursuant to
Chapter 11 of the United States Bankruptcy Code. In 1977, Mr. Wedekind received
a Bachelor of Science degree in Business Administration from the University of
Florida and, in 1979, he also received a Masters of Health and Hospital
Administration from the same school.
DONALD HOLMQUEST, M.D., J.D., Ph.D., received an undergraduate degree
in electrical engineering and computers then shifted to medicine. He continued
his education and completed a Ph.D. in physiology with a focus on computer
processing of physiological data. Following one year of internal medicine
training, he served for several years as a Scientist Astronaut with NASA. At
NASA, he was in the Apollo and Skylab programs, working to implement medical
experiements in space. After completeing his fellowship work and specialty
boards in nuclear medicine, Dr. Holmquest returned to academic medicine where he
worked as Associate Dean on the startup of the new medical school at Texas A&M
University. After leaving the new medical school, Dr. Holmquest spent several
years in private practice. During his years in private practice, Dr. Holmquest
completed law school. After completing law school, Dr. Holmquest began a
practice in healthcare law, which he has continued for almost twenty years.
During his practice in law, he has worked for numerous healthcare providers
and ventures and served on the Boards of Directors of two large national
hospital systems. More recently, Dr. Holmquest has begun to focus his
energies on small healthcare startup companies, particularly in the Internet
arena. Dr. Holmquest and is a member of many professional and non-professional
organizations including the American Fighter Pilots Association.
ITEM 10. EXECUTIVE COMPENSATION
The following table sets forth for the period ended December 31,
1999 all compensation received or accrued by the Chief Executive Officer and by
each of the other most highly compensated executive officers ("Named Executive
Officers"). As of the date hereof, the Company has not entered into employment
agreements with the
<PAGE>
Named Executive Officers. Before his resignation, the Company had an employment
agreement with Lawrence J. Wedekind, who served as Chief Executive Officer of
the Company.
For current executive officers, salaries paid as of December 31,
1999, were as follows:
<TABLE>
<CAPTION>
Annual Bonus Long-Term Compensation
Name and Principal Compensation(1)
Position(4) Salary(2) Restricted Stock
Awards(3)
<S> <C> <C> <C>
William J. Marciniak $76,000 - $100.00
Vice President of Marketing
Grant M. Gables $86,000 - $400
Executive Vice President, COO
R. Craig Christopher $76,000 - $250
VP of Product Fulfillment
Benjamin J. Scardello $42,000 - $250
VP of Managed Care Services
</TABLE>
H
(1) The named executives received no compensation for periods prior to April 7,
1998, the date of organization of Old MediQuik. Salaries reflected herein
are as of December 31, 1999.
(2) In 1999 salaries were deferred in amounts as follows: Mr. Marciniak,
$26,000; Mr. Gables, $22,000; Mr. Christopher $24,625; and Mr. Scardello,
$15,000. In 1998 salaries were deferred in amounts as follows: Mr. Gables,
$14,000; Mr. Marciniak, $14,000; and Mr. Christopher, $12,625.
(3) Based on an estimated value of $0.001 per share for shares of restricted
stock issued by Old MediQuik pursuant to the Stock Incentive Plan (defined
below). The issuers right to repurchase the shares of restricted stock
expired June 17, 1999.
(4) Each of the executives listed herein has been paid $8,000 per month since
January 1, 2000. As in previous years, if the Company experiences cash-flow
difficulties, the executives may not be paid the full amount of their
compensation in any given month. Further, such executives may not be paid
such deferred compensation in later months.
EXECUTIVE EMPLOYMENT AGREEMENTS
The Company has not entered into employment agreements with the
Named Executives Officers. On September 7, 1999, the Company entered into a
one year employment agreement with Mr. Wedekind which was renewable for
additional one year
<PAGE>
periods at Mr. Wedekind's option if his efforts resulted in providing the
Company with an additional 40,000 patients by the end of his initial term.
However, Mr. Wedekind resigned his position effective March 31, 2000.
Pursuant to his employment agreement with the Company, the Company paid Mr.
Wedekind a total of $15,000 in cash and 51,000 shares of Common Stock of the
Company. The Company intends to engage Mr. Wedekind as a consultant at $4,000
per month.
STOCK INCENTIVE PLAN
The Board of Directors of the Company has approved and adopted by
written consent, the MediQuik Services, Inc. Stock Incentive Plan (the "Stock
Incentive Plan"). The purpose of the Stock Incentive Plan is to provide deferred
stock incentives to certain key employees and directors of the Company who
contribute significantly to the long-term performance and growth of the Company.
The following description provides a summary of the Stock Incentive Plan. Such
summary does not purport to be complete.
GENERAL PROVISIONS OF THE STOCK INCENTIVE PLAN. The Stock Incentive
Plan is administered by the Board of Directors or a committee of the Board of
Directors duly authorized and given authority by the Board of Directors to
administer the Stock Incentive Plan (the Board of Directors or such designated
Committee as administrator of the Stock Incentive Plan shall be hereinafter
referred to as the "Board"). The Board has exclusive authority to administer the
Stock Incentive Plan including without limitation, to select the employees to be
granted awards under the Stock Incentive Plan, to determine the type, size and
terms of the awards to be made, to determine the time when awards will be
granted, and to prescribe the form of instruments evidencing awards made under
the Stock Incentive Plan. The Board is authorized to establish, amend and
rescind any rules and regulations relating to the Stock Incentive Plan as may be
necessary for efficient administration of the Stock Incentive Plan. Board action
with respect to the Stock Incentive Plan requires a majority vote of the members
of the Board taken at a meeting at which a quorum is present (currently three
directors).
Three types of awards are available under the Stock Incentive Plan:
(i) nonqualified stock options or incentive stock options, (ii) stock
appreciation rights, and (iii) restricted stock. An aggregate of 1,500,000
shares of Common Stock may be issued pursuant to the Stock Incentive Plan,
subject to adjustment to prevent dilution due to merger, consolidation, stock
split or other recapitalization of the Company.
The Stock Incentive Plan does not affect the right or power of the
Company or its stockholders to make or authorize any major corporate transaction
such as a merger, dissolution or sale of assets. Under terms of the Stock
Incentive Plan, if the Company is dissolved, liquidated or merged out of
existence, each participant will be entitled to a benefit as though he became
fully vested in all previous awards to him immediately prior
<PAGE>
to or concurrently with such dissolution, liquidation or merger. The Board may
provide that an option or stock appreciation right will be fully exercisable, or
that a share of restricted stock will be free of such restriction upon a change
in control of the Company.
The Stock Incentive Plan may be amended at any time and from time to
time by the Board of Directors but no amendment which increases the aggregate
number of shares of Common Stock that may be issued pursuant to the Stock
Incentive Plan will be effective unless it is approved by the stockholders of
the Company. The Stock Incentive Plan will terminate upon the earlier of the
adoption of a resolution by the Board of Directors terminating the Stock
Incentive Plan, or ten years from the date of the Stock Incentive Plan's initial
approval by the Board of Directors.
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The following table sets forth certain information regarding the
beneficial ownership of the Common Stock as of March 31, 2000 as to (i) each
person known by the Company to own beneficially more than 5% of the outstanding
Common Stock, (ii) each Director of the Company, (iii) each Executive Officer of
the Company and (iv) all Directors and Officers of the Company as a group.
<TABLE>
<CAPTION>
Name of Beneficial Owner Shares of Common Percent of Class (2)
Stock Owned (1)
<S> <C> <C>
Fisher Management Group, Inc.(3) 1,317,642 21.84%
3121 Buffalo Speedway, Ste. 5407
Houston, Texas 77098
Grant M. Gables(4) 972,756 16.13%
11549 Riverview Way
Houston, Texas 77077
Jocody Financial , Inc. 5773 474,543 7.87%
Woodway, Suite 290
Houston, Texas 77057
Howard B. Butler, Jr. 313,784 5.20%
7721 San Felipe
Houston, Texas 77063
Roger Cotrofeld, Jr. 306,637 5.08%
123 Mohawk Drive
Fort Plain, NY 13339
R. Craig Christopher 272,865 4.52%
8335 Ariel
Houston, Texas 77074
<PAGE>
<S> <C> <C>
William Marciniak (5) 332,373 5.51%
908 Antler
Schertz, Texas 78164
Benjamin J. Scardello (6) 171,450 2.84%
17003 Windrow Drive
Spring, Texas 77379
Lawrence J. Wedekind (7) 21,500 0.36%
16266 Salmon Drive
Spring, Texas 77379
Donald Holmquest 25,000 0.41%
109 Marrakesh
Bellaire, TX 77401
All Officers and Directors as a group 2,109,728 34.97%
(7 persons)
</TABLE>
(1) Under the rules of the Securities and Exchange Commission, a person is
deemed to be the beneficial owner of a security if such person has or
shares the power to vote or direct the voting of such security or the power
to dispose or direct the disposition of such security. A person is also
deemed to be a beneficial owner of any securities if that person has the
right to acquire beneficial ownership within 60 days. Accordingly, more
than one person may be deemed to be a beneficial owner of the same
securities. Unless otherwise indicated by footnote, the named entities or
individuals have sole voting and investment power with respect to the
Shares of Common Stock beneficially owned.
(2) Represents the number of shares of Common Stock beneficially owned by each
named person or group, expressed as a percentage of all of the shares of
such class outstanding as of such date without giving effect to 250,000
shares issuable pursuant to warrants held by consultants and advisors to
the Company.
(3) Such shares are attributable to Fisher Management Group, Inc. in its
capacity as general partner of various limited partnerships which each own
shares of Common Stock.
(4) Includes 474,543 shares held by Jocody Financial, Inc., a corporation
wholly owned by Mr. Gables' spouse.
(5) Includes 196,208 shares held by Mr. Marciniak's minor children
(6) Includes 30,708 shares held by Mr. Scardello's spouse.
(7) Includes 11,500 shares held by Greater Gulf Medical Alliance, Inc., of
which Mr. Wedekind is the sole shareholder and serves as president and
chief executive officer.
ITEM 12. CERTAIN RELATIONSHIP AND RELATED TRANSACTIONS
ACQUISITION OF ASSETS
<PAGE>
Effective April 7, 1998, MediQuik Services, L.L.C., a Nevada limited
liability company ("MSL"), transferred its interest in six provider agreements
to the Company in exchange for 2,750,000 shares of Common Stock (the "MSL
Shares"), the forgiveness of MSL's indebtedness to Old MediQuik in the amount of
$64,404, and the assumption by the Company of payment obligations under the 15%
Subordinated Debentures (the "Debentures") issued by MSL in the aggregate
principal amount of $130,000. The Debentures are payable in two equal
installments due on June 30, 1999 and December 31, 1999. The Debentures accrue
interest at a rate of 15% per annum, which is payable quarterly. Fisher
Management Group, Inc., which beneficially owns 22.20% of the outstanding Common
Stock, is the General Manager of MSL.
Jana J. Gables, Howard B. Butler, Jr., and Grant M. Gables acted as
promoters of the Company and Jacody Financial , Inc., a corporation owned by
Jana J. Gables, wife of Grant M. Gables, received 451,000 of the MSL Shares, as
a designee of MSL in proportion to its interest in the MSL Assets. Grant M.
Gables and Howard B. Butler, Jr. purchased 88,000 and 22,000 shares,
respectively, in connection with the organization of the Company for a purchase
price of $.01 per share.
Effective July 27, 1999, the Company acquired certain assets of
Scardello Marketing Group LLC ("SMG") in exchange for $25,000 in cash, the
forgiveness of SMG's indebtedness to the Company in the amount of $15,396, and
330,000 shares of Common Stock. The assets acquired from SMG include contract
rights, rights to assumed names, revenues and accounts receivable, customer
lists, books and records, claims or causes of action and computer hardware and
software. Benjamin J. Scardello, an executive officer of MediQuik, is the
managing member and 57.5% owner of SMG.
FINANCIAL CONSULTING AND OTHER SERVICE AGREEMENTS
Effective April 7, 1998 the Company entered into a Consulting
Agreement with The Fisher Group, an Oklahoma limited partnership ("Fisher") and
an affiliate of the Company, for acquisition and financial consulting services
to continue until terminated by either party. The Fisher agreement initially
provided for the payment of a monthly fee in the amount of $8,000 plus
reimbursement of expenses. In August, 1999, the Fisher agreement was amended,
reducing the monthly fee to $2,000 plus reimbursement of expenses. Fisher
Management Group, Inc., which beneficially owns 22.20% of the outstanding Common
Stock, is the general partner of Fisher. The Company believes that the Fisher
agreement provides for services on terms no less favorable to the Company than
those which would be obtained from unrelated parties.
Effective April 7, 1998 the Company entered into a Consulting
Agreement with Jocody Financial, Inc. ("Jocody"), an affiliate of the Company,
for acquisition and financial consulting services to continue until terminated
by either party. The Jocody agreement initially provided for the payment of a
monthly fee in the amount of $8,000 plus reimbursement of expenses. In August,
1999, the Jocody agreement was amended, reducing the monthly fee to $2,000 plus
reimbursement of expenses. Jocody owns 8.00% of the Common Stock of the Company
and is wholly-owned by Jana J. Gables. The
<PAGE>
Company believes that the Jocody agreement provides for services on terms no
less favorable to the Company than those which would be obtained from unrelated
parties.
In June, 1999, the Company entered into an Agreement with Scardello
Marketing Group LLC ("SMG") for SMG to assist in the acquisition of a diabetic
pharmaceutical supply company ("DPS, Co.") by MediQuik and in the financing of
that acquisition. Upon the acquisition of DPS, Co. by the Company, SMG will
receive 200,000 shares of MediQuik Common Stock or options to acquire such
MediQuik Common Stock in consideration for the successful acquisition. In
addition, if the Company acquires DPS, Co., SMG will receive 100,000 shares of
Common Stock or options to acquire such MediQuik Common Stock in consideration
for arranging financing for the acquisition on terms as set forth in the
Agreement, whether or not MediQuik utilizes the financing source. Benjamin J.
Scardello, an executive officer of MediQuik, is the managing member and 57.5%
owner of SMG. The Company believes that the Scardello Agreement provides for
services on terms no less favorable to the Company than those that would be
obtained from unrelated parties.
On August 2, 1999, the Company entered into an Independent Contractor
Agreement (the "Agreement") with Chronic Disease Solutions, L.C., an affiliate
of Mr. Wedekind ("Chronic Disease Solutions"). Under the Agreement, Chronic
Disease Solutions agrees to market the Company's products and services to
patients covered by third party payor agreements.
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K.
There were no reports on Form 8-K filed during the last quarter of
1999.
<PAGE>
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
Exhibit No. Description of Exhibit
- ----------- ----------------------
<S> <C>
*(b)(3)(i) Certificate of Incorporation of MediQuik
*(b)(3)(ii) Bylaws of MediQuik
*(b)(10) Material Contracts
- Ancillary Services participating Provider Agreement,
dated February 6, 1998 for PPO/EPO Networks between
MediQuik and National Healthcare Alliance, Inc.
- Participating Facility Agreement, dated February 1,
1998 between MediQuik and Multiplan, Inc.
- Health Care Service Ancillary Agreement, dated April
7, 1998 between MediQuik and USA Managed Care Organization,
Inc.
- Letter Agreement, dated May 25, 1999, between MedQuik
and Cooperative Health Services of Colorado
- 1998 Mail Order and Mail Order Testing Compliance
Agreement dated October 2, 1998 between MediQuik and
Bayer Corporation
- 1999 Nursing Home/Long Term Care/Home Health Care
Distributor Agreement dated February 9, 1999, between
MediQuik and Bayer Corporation
- Lease Agreement, dated May 7, 1999, between Bancroft
Building Houston, LP and MediQuik
- Letter Agreement, dated June 18, 1999, between MediQuik
and SMG regarding acquisition of a diabetic pharmaceutical
supply company
- Provider Agreement, effective July 1, 1999, between
MediQuik and Advantage Care Network, Inc.
- Employment Agreement, effective September 7, 1999,
between MedQuik and Lawrence J. Wedekind
- Ancillary Provider Agreement dated February 27, 1998,
between MediQuik and Global Medical Solutions, Inc.
<PAGE>
<S> <C>
- Agreement, dated August 6, 1999, between MediQuik and
Murray Hill Communications, Inc.
(b)(21) Subsidiaries of the Registrant
(b)(27) Financial Data Schedule
</TABLE>
*Previously filed with the Commission
<PAGE>
Pursuant to the requirements of Sections 13 of 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Date: April 19, 2000 Mediquik Services, Inc.
By: /s/ Grant M. Gables
-----------------------
Grant M. Gables, Executive Vice President, COO
<PAGE>
EXHIBIT (b)(21)
Subsidiaries of MediQuik
MediQuik formed a subsidiary in May, 1999 known as ChronicRx.com LLC.
It is organized in the state of Texas and does business under the name
ChronicRx.com.
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM MEDIQUIK
SERVICES, INC'S FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 1999 AND
FOR THE PERIOD FROM APRIL 7, 1998 (DATE OF INCORPORATION) TO DECEMBER 31, 1998
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C> <C>
<PERIOD-TYPE> YEAR YEAR
<FISCAL-YEAR-END> DEC-31-1999 DEC-31-1998
<PERIOD-START> JAN-01-1999 JAN-01-1998
<PERIOD-END> DEC-31-1999 DEC-31-1998
<CASH> 47,424 7,578
<SECURITIES> 0 0
<RECEIVABLES> 230,397 50,785
<ALLOWANCES> 88,702 0
<INVENTORY> 21,737 79,093
<CURRENT-ASSETS> 210,856 153,456
<PP&E> 74,850 249
<DEPRECIATION> (7,215) (29)
<TOTAL-ASSETS> 1,419,018 215,327
<CURRENT-LIABILITIES> 882,687 534,564
<BONDS> 0 0
0 0
0 0
<COMMON> 6,033 4,849
<OTHER-SE> 0 0
<TOTAL-LIABILITY-AND-EQUITY> 536,331 (319,237)
<SALES> 982,292 372,226
<TOTAL-REVENUES> 0 0
<CGS> 724,605 317,553
<TOTAL-COSTS> 724,605 317,553
<OTHER-EXPENSES> 139,874 9,141
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> (24,260) (28,310)
<INCOME-PRETAX> (3,129,659) (829,854)
<INCOME-TAX> 0 0
<INCOME-CONTINUING> 0 0
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> 0 0
<EPS-BASIC> (0.57) (0.21)
<EPS-DILUTED> (0.57) (0.21)
</TABLE>
